Who are Alkermes plc's main suppliers?

Alkermes plc (ALKS) key suppliers include: Amneal Pharmaceuticals, Inc., Altamira Therapeutics Ltd.. View the full supplier network at chainsifter.com/chain/ALKS.

Who are Alkermes plc's major customers?

Alkermes plc (ALKS) key customers include: SPECIALTY-PHARMACIES, Bank of America Corporation, JOINT-BOOKRUNNER-BOFA-SECURITIES-INC, TOPCO-BORROWER-ALKERMES-INC, U-S-BORROWER-ALKERMES-FINANCE-LLC. View the full customer network at chainsifter.com/chain/ALKS.

What sector is Alkermes plc in?

Alkermes plc (ALKS) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

Alkermes plc (ALKS): 9 Verified Supply Chain Relationships

2Suppliers

5Customers

2Debt Items

20Related Chains

Source-Backed Evidence Depth

Alkermes plc (ALKS) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

52Total relationships

2Distinct source URLs

47High confidence

0.833Average confidence

2026-10-28Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Alkermes plc Suppliers

Ticker	Name	Confidence	Evidence
AMRX	Amneal Pharmaceuticals, Inc.	85%	Reciprocal relationship from AMRX graph: Reciprocal relationship from ALKS graph: Reciprocal relationship from AMRX graph: pment purchase Property, plant and equipment $ — $ 160 Alkermes Plc Inventor…
CYTOF	Altamira Therapeutics Ltd.	72%	Reciprocal relationship from CYTOF graph: payors, including private insurers, and some state laws require pharmaceutical companies to comply with the pharmaceutical industry’s voluntary compliance gu…

Alkermes plc Customers

Ticker	Name	Confidence	Evidence
SPECIALTY-PHARMACIES	SPECIALTY-PHARMACIES	90%	Product sales, net are recognized when the customer obtains control of the product, which is when the product has been received by the customer. During the three months ended March 31, 2026 and 2025,…
BAC	Bank of America Corporation	62%	Reciprocal relationship from BAC graph: Reciprocal relationship from ALKS graph: Reciprocal relationship from BAC graph: Reciprocal relationship from ALKS graph: Reciprocal relationship from BAC grap…
JOINT-BOOKRUNNER-BOFA-SECURITIES-INC	JOINT-BOOKRUNNER-BOFA-SECURITIES-INC	62%	on quoted market price indications (Level 2 in the fair value hierarchy) and which may not be representative of actual values that could have been, or will be, realized in the future, was $ 1,542.6 m…
TOPCO-BORROWER-ALKERMES-INC	TOPCO-BORROWER-ALKERMES-INC	62%	on quoted market price indications (Level 2 in the fair value hierarchy) and which may not be representative of actual values that could have been, or will be, realized in the future, was $ 1,542.6 m…
U-S-BORROWER-ALKERMES-FINANCE-LLC	U-S-BORROWER-ALKERMES-FINANCE-LLC	62%	on quoted market price indications (Level 2 in the fair value hierarchy) and which may not be representative of actual values that could have been, or will be, realized in the future, was $ 1,542.6 m…

Alkermes plc Debt Obligations

Instrument	Description	Confidence	Evidence
ALKS-DEBT	Debt stack $1.5B	90%	Market cache reports total debt of $1.5B.
ALKS-DEBT-7681	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2013-03-31.

Alkermes plc Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Alkermes plc.

Alkermes plc Ownership

Holder	Name	Confidence	Evidence
ALKS-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC	VANGUARD CAPITAL MANAGEMENT LLC	95%	13F/ownership overlay lists VANGUARD CAPITAL MANAGEMENT LLC; shares held 14,854,794; value $525.3B; as of 2026-03-31.
ALKS-OWNER-BLACKROCK-INC	BlackRock, Inc.	95%	13F/ownership overlay lists BlackRock, Inc.; shares held 28,314,410; ownership 16.88%; value $1.00T; as of 2026-03-31.
ALKS-OWNER-BAKER-BROS-ADVISORS-LP	BAKER BROS. ADVISORS LP	95%	13F/ownership overlay lists BAKER BROS. ADVISORS LP; shares held 10,012,267; value $354.0B; as of 2026-03-31.
ALKS-OWNER-MORGAN-STANLEY	MORGAN STANLEY	95%	13F/ownership overlay lists MORGAN STANLEY; shares held 5,176,077; value $160.8B; as of 2026-03-31.
ALKS-OWNER-VANGUARD-PORTFOLIO-MANAGEMENT-LLC	VANGUARD PORTFOLIO MANAGEMENT LLC	95%	13F/ownership overlay lists VANGUARD PORTFOLIO MANAGEMENT LLC; shares held 9,511,112; value $336.3B; as of 2026-03-31.
ALKS-OWNER-STATE-STREET-CORP	STATE STREET CORP	95%	13F/ownership overlay lists STATE STREET CORP; shares held 9,465,286; value $334.7B; as of 2026-03-31.
ALKS-OWNER-RENAISSANCE-TECHNOLOGIES-LLC	RENAISSANCE TECHNOLOGIES LLC	95%	13F/ownership overlay lists RENAISSANCE TECHNOLOGIES LLC; shares held 6,160,428; value $217.8B; as of 2026-03-31.
ALKS-OWNER-AMERICAN-CENTURY-COMPANIES-INC	AMERICAN CENTURY COMPANIES INC	95%	13F/ownership overlay lists AMERICAN CENTURY COMPANIES INC; shares held 6,072,103; value $214.7B; as of 2026-03-31.
ALKS-OWNER-DIMENSIONAL-FUND-ADVISORS-LP	DIMENSIONAL FUND ADVISORS LP	95%	13F/ownership overlay lists DIMENSIONAL FUND ADVISORS LP; shares held 4,522,378; value $159.9B; as of 2026-03-31.
ALKS-OWNER-PRICE-T-ROWE-ASSOCIATES-INC-MD	PRICE T ROWE ASSOCIATES INC /MD/	95%	13F/ownership overlay lists PRICE T ROWE ASSOCIATES INC /MD/; shares held 4,664,576; value $164.9M; as of 2026-03-31.
ALKS	Alkermes plc	82%	Reed Joshua \| SVP, Chief Financial Officer \| option_exercise \| 66430 shares
ALKS	Alkermes plc	82%	Pops Richard F \| Director and CEO \| option_exercise \| 88843 shares
ALKS	Alkermes plc	82%	Gaffin David Joseph \| EVP, CLO, Alkermes, Inc. \| sell \| 237660 shares
ALKS	Alkermes plc	82%	Hopkinson Craig C. \| EVP R&D, Chief Medical Officer \| sell \| 9000 shares
ALKS	Alkermes plc	82%	Jackson Blair Curtis \| EVP, Chief Operating Officer \| option_exercise \| 94900 shares
ALKS	Alkermes plc	82%	Nichols Christian Todd \| SVP, Chief Commercial Officer \| sell \| 6000 shares
ALKS	Alkermes plc	82%	Parisi Samuel Joseph \| VP, Finance (Interim PAO) \| sell \| 15033 shares
ALKS	Alkermes plc	82%	Pops Richard F \| Director and CEO \| option_exercise \| 88843 shares
ALKS	Alkermes plc	82%	Reed Joshua \| SVP, Chief Financial Officer \| option_exercise \| 66430 shares
ALKS	Alkermes plc	82%	Gaffin David Joseph \| EVP, CLO, Alkermes, Inc. \| option_exercise \| 6866 shares
ALKS	Alkermes plc	82%	Hopkinson Craig C. \| EVP R&D, Chief Medical Officer \| option_exercise \| 6866 shares
ALKS	Alkermes plc	82%	Jackson Blair Curtis \| EVP, Chief Operating Officer \| option_exercise \| 3695 shares
ALKS	Alkermes plc	82%	Nichols Christian Todd \| SVP, Chief Commercial Officer \| option_exercise \| 5410 shares
ALKS	Alkermes plc	82%	Parisi Samuel Joseph \| VP, Finance (Interim PAO) \| option_exercise \| 808 shares
ALKS	Alkermes plc	82%	Parisi Samuel Joseph \| VP, Finance (Interim PAO) \| option_exercise \| 672 shares
ALKS	Alkermes plc	82%	Nichols Christian Todd \| SVP, Chief Commercial Officer \| option_exercise \| 6407 shares
ALKS	Alkermes plc	82%	Jackson Blair Curtis \| EVP, Chief Operating Officer \| option_exercise \| 8738 shares
ALKS	Alkermes plc	82%	Hopkinson Craig C. \| EVP R&D, Chief Medical Officer \| option_exercise \| 3414 shares
ALKS	Alkermes plc	82%	Gaffin David Joseph \| EVP, CLO, Alkermes, Inc. \| option_exercise \| 7689 shares
ALKS	Alkermes plc	82%	Hopkinson Craig C. \| EVP R&D, Chief Medical Officer \| option_exercise \| 3414 shares

Alkermes plc Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
AMRX	Amneal Pharmaceuticals, Inc.	100.00	1	['supplier']
CYTOF	Altamira Therapeutics Ltd.	100.00	1	['supplier']
BAC	Bank of America Corporation	100.00	1	['customer']
CHRS	Coherus Oncology, Inc.	50.00	2
HTGC	Hercules Capital, Inc.	50.00	2
DXR	Daxor Corporation	50.00	2
HIW	Highwoods Properties, Inc.	50.00	2
ORANY	ORANGE	50.00	2
SPH	Suburban Propane Partners, L.P.	50.00	2
UP	Wheels Up Experience Inc.	50.00	2
BML-PG	Bank of America Corporation	50.00	2
GOOD	Gladstone Commercial Corporation	50.00	2
JANX	Janux Therapeutics, Inc.	50.00	2
KFRC	Kforce Inc.	50.00	2
OCS	Oculis Holding AG	50.00	2
SEPN	Septerna, Inc.	50.00	2
MLYS	Mineralys Therapeutics, Inc.	50.00	2
SPRY	ARS Pharmaceuticals, Inc.	50.00	2
SENEB	Seneca Foods Corporation	50.00	2
SNYNF	Sanofi	50.00	2

Alkermes plc Supply Chain